Incyte, Hengrui In 'Biggest Ever' China Pharma Out-Licensing Deal

In an alliance that illustrates the growing attractiveness of rising innovative R&D capabilities at selected Chinese pharma firms, the US oncology-focused company Incyte Corp. has acquired development and commercialization rights in most global markets to SHR-1210, a PD-1-targeting antibody developed by Jiangsu Hengrui Medicine Co. Ltd.

In an alliance that illustrates the growing attractiveness of rising innovative R&D capabilities at selected Chinese pharma firms, the US oncology-focused company Incyte Corp. has acquired development and commercialization rights in most global markets to SHR-1210, a PD-1-targeting antibody developed by Jiangsu Hengrui Medicine Co. Ltd.

The deal is worth $25m up front and up to $770m in milestone fees, plus tiered royalties. Hengrui retains rights...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category